The therascreen EGFR Plus RGQ PCR Kit enables sensitive detection of all currently known activating and resistance EGFR mutations – including T790M and C797S. The flexible assay tests both FFPE tissue and plasma samples and provides next-day results with automated data analysis (5).

Mutation analysis in NSCLC is the gold-standard test for driver mutations in EGFR, the results of which empower oncologists to tailor patients’ treatment.